Steroidal quinols and their use for antioxidant therapy

Details Steroidal quinols and their use for antioxidant therapy Steroidal quinols and their use for antioxidant therapy

2006-04-11

2006-04-11

Badio, Barbara P. (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

C552S612000

Reexamination Certificate

active

07026306

ABSTRACT:
The present invention relates to novel estrogen-related steroidal quinols and their use as prodrugs for phenolic estrogens and estrogen analogs. The quinols of the present invention provide improved physicochemical properties, increased bioavailability, and improved distribution into tissues and penetration across the blood-brain barrier when compared to phenolic estrogens and estrogen analogs.

REFERENCES:
patent: 2910486 (1959-10-01), Jiu
patent: 2950291 (1960-08-01), Jin
patent: 5108996 (1992-04-01), Claussner et al.
patent: 5395831 (1995-03-01), Gemmill, Jr. et al.
patent: 5552395 (1996-09-01), Gemmill, Jr. et al.
patent: 5554601 (1996-09-01), Simpkins et al.
patent: 5859001 (1999-01-01), Simpkins et al.
patent: 5891878 (1999-04-01), Beasley et al.
patent: 6197833 (2001-03-01), Simpkins et al.
patent: 6319914 (2001-11-01), Simpkins et al.
patent: 2003/0050295 (2003-03-01), Pang
patent: 2003/0105167 (2003-06-01), Dykens
patent: 2004/0214806 (2004-10-01), Pang
patent: WO 03/084978 (2003-10-01), None
Numazawa et al., Chem. Pharm. Bull., vol. 37(8), pp. 2058-2062, 1989.
Breuer, H. and Koster, G “Interaction Between Oestrogens and Neurotransmitters at the Hypophysial-Hypothalamic Level”Journal of Steroid Biochemistry, 1974, pp. 961-967, vol. 5.
Hiemke, C. et al. “Actions of Sex Hormones on the Brain”Prog. Neuro-Psychopharmacol&Biol.Psychiat, 1992, pp. 377-388, vol. 16.
Liang, Y. et al. “Membrane Fluidity Effects of Estratrienes”Brain Research Bulletin, 2001, pp. 661-668, vol. 54, No. 6.
Milic, D. et al. “X-Ray Crystal Structure of 10β-Hydroxy-4β,5β-expoxyerstr-1-ene-3,17-dione and Antitumor Activity of its Congeners”Molecules, 1999, pp. 338-352, vol. 4.
Milic, D. et al. “The Synthesis and Biological Evaluation of A-Ring Substituted Steroidal p-Quinones”Tetrahedron, 1997, pp. 14073-14084, vol. 53, No. 41.
Milic, D. et al. “Structure and Reactivity of Steroidal Quinones”J. Serb. Chem. Soc., 1997, pp. 755-768, vol. 62, No. 9.
Ohe, T. et al. “Novel Metabolic Pathway of Estrone and 17β-Estradiol Catalyzed by Cytochrome P-450”Drug Metabolism and Disposition, 2000, pp. 110-112, vol. 28, No. 2.
Prokai, L. et al. “Synthesis and Biological Evaluation of 17β-Alkoxyestra-1,3,5(10)-trienes as Potential Neuroprotectants Against Oxidative Stress”J. Med. Chem., 2001, pp. 110-114, vol. 44.
Solaja, B. et al. “A Novel m-CPBA Oxidation: p-Quinols and Epoxyquinols from Phenols”Tetrahedron Letters, 1996, pp. 3765-3768, vol. 37, No. 21.
Galdecki, Z., P. et al. (1987) “Structure of 2,4-Dibromo-10β, 17β-dihydroxy-1,4-estradien-3-one”Acta Cryst. vol. c43, pp. 967-968.
Kupfer, Rene, Long Yu Liu, Alban J. Allentoff, John A. Thompson (2001) “Comparisons of Hydroperoxide Isomerase and Monooxygenase Activities of Cytochrome P450 for Conversions of Allylic Hydroperoxides and Alcohols to Epoxyalcohols and Diols: Probing Substrate Reorientation in the Active Site”Biochemistry40:11490-11501.
McCullough, Louise D. and Patricia D. Hurn (Jul. 2003) “Estrogen and Ischemic Neuroprotection: an integrated view”Trends in Endocrinology and Metabolism14(5):228-235.
Nilsen, Jon and Roberta Diaz Brinton (Jan. 2002) “Impact of Progestins on Estrogen-Induced Neuroprotection: Synergy by Progesterone and 19-Norprogesterone and Antagonism by Medroxyprogesterone Acetate”Endocrinology143(1):205-212.
Numazawa, Mitsuteru, Kumiko Hoshi, Katsuhiko Kimura (1989) “Oxygenation of 2,4-Dibromoestrogens with Nitric Acid: A New Synthesis of 19-Nor Steroids”Chem. Pharm Bull.37(8):2058-2062.
Ohe, Tomoyuki, Masaaki Hirobe, Tadahiko Mashino (2000) “Novel Metabolic Pathway of Estrone and 17β-Estradiol Catalyzed by Cytochrome P-450”Drug Metabolism and Disposition28(2):110-112.
Nilsen, Jon and Roberta Diaz Brinton (Sep. 2, 2003) “Divergent impact of progesterone and medroxyprogestoner acetate (Provera) on nuclear mitogen-activated protein kinase signaling”PNASvol. 100, No. 18, pp. 10506-10511.
Prokai Laszlo, et al. (Sep. 30, 2003) “Quninol-based cyclic antioxidant mechanism in estrogen neuroprotein”PNASvol. 100, No. 20, pp. 11741-11746.
Prokai, Laszlo, et al. (2003) “Short Communication: Quinol-based Metabolic Cycle for Estrogen in Rat Liver Microsomes”Drug Metabolism and Dispositionvol. 31, No. 6, pp. 701-704.
Prokai-Tatrai, Katalin and Laszlo Prokai (2003) “Modifying peptide properties by prodrug design for enhanced transport into the CNS”Progress in Drug Research. vol. 61, pp. 155-188.
Prokai, Laszlo, Katalin Prokai-Tatrai, and Nicholas Bodor (2000) “Targeting Drugs to the Brain by Redox Chemical Delivery Systems”Med Res Rev, vol. 20, No. 5, pp. 367-416.
Beers, M.H. and R. Berkow, Editors, The Merck Manual of diagnosis and therapy, pp. 471-473 and pp. 1942-1944 (1999) Merck Research Laboratories, Whitehouse Station, N.J. USA.
Lupon, P. et al. (1983) “Photooxygenierung von Oestrogenen: Eine Neu 19-Norsteroid-Synthese” Verlagsgesellschaft, Weinheim, DE, vol. 95, No. 9, p. 757.
Sedee, A.G. J. et al. (1983) “A sintesis for p-quinol compounds from phenols fused with other saturated rings”Tetrahedron Letters24(51):5779-5780.

Affiliated with

Also associated with

Rating

Steroidal quinols and their use for antioxidant therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Steroidal quinols and their use for antioxidant therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Steroidal quinols and their use for antioxidant therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3582534